A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)

Trial Profile

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs 18F-CTT 1057 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Cancer Targeted Technology
  • Most Recent Events

    • 06 Jun 2017 Results (n=5) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2016 According to Cancer Targeted Technology media release,this trial is expected to conclude in mid 2017.
    • 12 Dec 2016 According to Cancer Targeted Technology media release, the first patient in this trial was imaged in early November and the study is supported by a $2M Small Business Innovation Research (SBIR) grant.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top